Results 51 to 60 of about 635,296 (203)
Nature Communications, 2016 IRS proteins are scaffolds that can activate survival signalling pathways. In this study, the authors identified IRS4 as a potential oncogene in breast cancer that leads to the constitutive activation of PI3K/AKT signalling and thus confers resistance to
Gerjon J. Ikink +3 more
doaj +1 more source
Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy
Frontiers in Pharmacology, 2021 MYC, as a well-known oncogene, plays essential roles in promoting tumor occurrence, development, invasion and metastasis in many kinds of solid tumors and hematologic neoplasms.
Yihui Zhou +10 more
doaj +1 more source
Id Proteins - Tumor Markers or Oncogenes? [PDF]
Cancer Biology & Therapy, 2002 The Id (Inhibitor of differentiation or Inhibitor of DNA-binding) proteins act as dominant negative inhibitors of differentiation-specific basic Helix-Loop-Helix (bHLH) transcription factors. Id proteins negatively regulate cellular differentiation and they induce proliferation by modulating different cell cycle regulators both by direct and indirect ...
Jens, Hasskarl, Karl, Münger
openaire +2 more sources
Life Science Alliance, 2018 The authors apply telomeric chromatin analysis to identify factors that accumulate at telomeres during cellular transformation, promoting telomere replication and repair and counteracting oncogene-borne telomere replication stress. Telomeres play crucial
Jana Majerska +3 more
doaj +1 more source
Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy
Chinese Journal of Lung Cancer, 2022 Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors.
Lin JIANG +4 more
doaj +1 more source
The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb. [PDF]
, 2019 Overexpression of the oncogene MYBL2 (B-Myb) is associated with increased cell proliferation and serves as a marker of poor prognosis in cancer. However, the mechanism by which B-Myb alters the cell cycle is not fully understood.
Ananthapadmanabhan, Varsha +8 more
core
The complex journey of targeting RAS in oncology
BMC CancerGiven the prevalence of RAS mutations in various cancers, personalized therapeutic approaches, guided by molecular markers, are essential. Farnesyltransferase inhibitors (FTIs) have emerged as potential therapeutic options; however, they also face ...
Katarzyna Wasiak +6 more
doaj +1 more source
Biology of Sex Differences, 2020 Hepatocellular carcinoma (HCC) is the most common liver cancer and is highly malignant. Male prevalence and frequent activation of the Ras signaling pathway are distinct characteristics of HCC.
Huiling Li +13 more
doaj +1 more source
Epigenetic modulation reveals differentiation state specificity of oncogene addiction
Nature Communications, 2021 Epigenetic mechanisms associated with the differentiation state of cancer cells and their heterogeneity influence tumor responses to oncogene-targeted therapies. In this study, the authors perform an epigenetic compound screen and single-cell analysis in
Mehwish Khaliq +3 more
doaj +1 more source
Point mutations of the P53 gene, human hepatocellular carcinoma and aflatoxins [PDF]
, 1993 The tumor suppressor p53 exerts important protective functions towards DNA-damaging agents. Its inactivation by allelic deletions or point mutations within the P53 gene as well as complex formation of wildtype p53 with cellular or viral proteins is a ...
Alexander L. Gerbes +40 more
core +1 more source